|
Daily Medical Update
Crohn disease including Crohn colitis
Sunday, April 12, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Inflammopharmacology (2025) - Network Meta-Analysis
Key Findings
- Mirikizumab increased clinical response by 69% versus placebo (61.0% vs 36.6%; RR 1.69, 95% CI 1.35-2.10; NNT 4).
- Clinical remission rose by 74% (37.1% vs 20.0%; RR 1.74) and endoscopic remission by 92% (28.7% vs 15.4%; RR 1.92).
- Serious adverse events were reduced (5.2% vs 9.1%; RR 0.53), with lower treatment discontinuation (2.5% vs 7.5%; RR 0.33).
📋 Practice Implication: Mirikizumab is a credible escalation option for moderate-to-severe Crohn disease, including biologic-exposed patients, when clinicians want both induction efficacy and a favorable short-term safety signal.
|
Inflammatory bowel diseases (2026) - Network Meta-Analysis
Key Findings
- Adalimumab plus thiopurines produced the largest clinical remission benefit versus placebo (RR 2.87, 95% CI 1.99-4.14; risk difference 35.3%; NNT 3).
- Other effective induction options increased clinical remission versus placebo, including guselkumab (RR 2.50), adalimumab monotherapy (RR 2.46), infliximab plus thiopurines (RR 2.43), and ustekinumab (RR 2.04).
- For endoscopic remission, risankizumab showed the largest effect size (RR 3.48, 95% CI 2.18-5.58; risk difference 17.4%).
📋 Practice Implication: When rapid induction is the goal, combination anti-TNF plus thiopurine therapy remains a benchmark regimen, while IL-23 pathway agents provide strong alternatives for patients needing a different efficacy-safety balance.
|
Journal of Crohn's & colitis (2025) - Network Meta-Analysis
Key Findings
- Video capsule endoscopy showed 89.6% sensitivity, 86.2% specificity, and 71.5% diagnostic accuracy for small-bowel Crohn disease, outperforming MRE and CTE.
- VCE ranked highest for diagnostic performance (P-score .97) and significantly increased diagnostic accuracy for proximal small-bowel disease versus the other modalities.
- Capsule retention occurred in 3.3% of cases.
📋 Practice Implication: If small-bowel Crohn disease remains suspected after standard evaluation and patency risk is acceptable, capsule endoscopy should move earlier in the diagnostic pathway, especially for suspected proximal disease.
|
Journal of Crohn's & colitis (2026) - Meta-Analysis
Key Findings
- Crohn disease was associated with higher colorectal cancer incidence (SIR 2.20, 95% CI 1.69-2.86), including colon cancer (SIR 2.06) and rectal cancer (SIR 1.75).
- Cancer risk increased in colonic disease (SIR 3.29) and ileocolonic disease (SIR 4.13) compared with ileal disease (SIR 1.95).
- Small-bowel cancer risk increased markedly overall (SIR 17.18) and was highest in ileal (SIR 44.85) and ileocolonic disease (SIR 21.44).
📋 Practice Implication: Cancer surveillance in Crohn disease should be phenotype-specific, with more explicit counseling and follow-up planning for patients with long-standing colonic, ileocolonic, or ileal involvement.
|
Inflammatory bowel diseases (2026) - Meta-Analysis
Key Findings
- Initial surgery had lower reoperation or subsequent surgery rates than medical therapy and percutaneous drainage (21% vs 48% and 47%, respectively).
- Compared with initial surgery, percutaneous drainage and medical therapy increased the odds of later surgical intervention (OR 5.28 and OR 4.40, respectively).
- Percutaneous drainage reduced overall postintervention complications versus initial surgery (OR 0.48, 95% CI 0.23-0.96), and adjunctive exclusive enteral nutrition reduced subsequent surgery (OR 0.26).
📋 Practice Implication: For Crohn-related intra-abdominal abscess, antibiotics alone should be reserved for select cases; most patients need a source-control strategy with drainage or surgery and an early plan for definitive management.
|
|
Recent Crohn disease syntheses emphasize stronger evidence for targeted induction therapy, more sensitive small-bowel diagnostics, and tighter long-term risk stratification. Mirikizumab and anti-TNF/thiopurine combination strategies improved induction outcomes, while capsule endoscopy outperformed MRE and CTE for proximal small-bowel disease. Separate meta-analyses reinforce the need for phenotype-specific cancer surveillance and structured source-control decisions for intra-abdominal abscesses.
|
|